Gundlach warns next US recession could trigger a fiscal crunch as bond haven status fades

Korean Won Extends Losing Streak to Fourth Session Amid Fed's Hawkish Stance and Risk Aversion

Why Archer and Joby Stocks Are Falling as Oil and Treasury Yields Rise

AstraZeneca’s ATTR-CM Imaging Sub-study Wraps Up, Setting the Stage for New Data Insights

Bond Yields at 5%, Oil at $120, VIX at 25? The Market's Nightmare Scenario Is Rapidly Becoming Reality

Intercont says not commenting on short-term market volatility

Capital Markets Warns of Rising Odds for a U.S. Stock Correction, Citing Midterm Election Risks and AI Trade Instability

Wall Street's Deceptive Calm Meets Bond Market's Stern Warning: As VIX Falls Silent, Are Treasury Yields the New Fear Barometer for Equities?

BridgeBio Pharma presents new analyses from Phase 3 ATTRibute-CM study

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

Ionis, AstraZeneca ATTR-CM trial did not meet primary endpoint

Japanese Shares Rise Ahead of Federal Reserve Chair's Rate Outlook; Oil Falls

Bayer’s MOSAIC-TTR Study: Real-World Data Push for Acoramidis in ATTR-CM

BridgeBio Pharma doses first patient in ASCEND-ATTR trial

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

Alert Signals Intensify: UBS Flags U.S. Stock Market Fragility at Two-Year High, Echoing Pattern That Preceded VIX Spike

Alnylam to present new clinical data on ATTR, hypertension at ESC Congress

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

The Bond Selloff is Rattling Investors, but Here's Why They Shouldn't Expect a Deeper Stock Downturn